Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label MK3(MK-3682/grazoprevir/ruzasvir1). Show all posts
Showing posts with label MK3(MK-3682/grazoprevir/ruzasvir1). Show all posts
Friday, September 29, 2017

TGIF HCV Review - Merck Discontinues MK-3682B and MK-3682C Development Programs

›
Happy Friday! Here are a few updates on viral hepatitis you may have missed this week. Quick Links Weekly news recap at HepCBC . In T...
Sunday, August 20, 2017

(grazoprevir-ruzasvir-uprifosbuvir) Shorter anti-HCV regimen effective in patients with or without cirrhosis

›
In Case You Missed It Full Text Shortening the duration of therapy for chronic HCV Lancet Published online August 9, 2017 PDF provided b...
Saturday, July 15, 2017

Hepatitis C Genotype 3 - FDA Approved And Soon To Be Approved Therapies

›
September: Updated AASLD IDSA HCV Guidance This page was updated on Aug 3, 2017 to include AbbVie's FDA approval of MAVYRET™ (glecapre...
Friday, June 30, 2017

Pangenotypic regimens and the next generation hepatitis C virus therapy

›
The latest issue of Clinical Liver Disease Clinical Liver Disease (CLD) is a digital educational resource published on behalf of the Ameri...
Thursday, May 18, 2017

The Changing HCV Landscape: Pangenotypic Regimens

›
Gastroenterology & Endoscopy News Review Articles MAY 18, 2017 The Changing HCV Landscape: Update on Treatment Toward the Fu...
Friday, April 28, 2017

Triple combination cures most hepatitis C patients with prior DAA treatment failure

›
Triple combination cures most hepatitis C patients with prior DAA treatment failure Liz Highleyman Produced in collaboration with hivandh...
Saturday, April 22, 2017

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C

›
Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C Merck ( MRK ), known as MSD...
Wednesday, April 5, 2017

Merck to Present New Data on (elbasvir and grazoprevir) and MK-3682B at International Liver Congress™ 2017

›
Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chro...
Thursday, February 23, 2017

With hep C franchises languishing, Merck’s MK-3682 goes from blockbuster to bomb

›
With hep C franchises languishing, Merck’s MK-3682 goes from blockbuster to bomb by John Carroll A little less than three years after acq...
Tuesday, February 21, 2017

Novel emerging treatments for hepatitis C infection: a fast-moving pipeline

›
Of Interest January 18, 2017 - Hepatitis C Treatment: What to Expect in 2017 November 2016 - Summary for AASLD 2016 for Hepatitis C -...